---
title: "Biocon Ltd (BIOCON) — Share Price, Financials & Analysis"
symbol: "BIOCON"
company: "Biocon Ltd"
canonical: "https://tapetide.com/stocks/BIOCON"
isin: "INE376G01013"
nse_symbol: "BIOCON"
bse_code: "532523"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 62453.58
generated_at: "2026-09-13T20:15:41.444Z"
---

# Biocon Ltd (BIOCON)

Canonical page: https://tapetide.com/stocks/BIOCON

## Company

- **NSE Symbol:** BIOCON
- **BSE Code:** 532523
- **ISIN:** INE376G01013
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2004-04-07
- **CEO:** Dr. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc.
- **Employees:** 16420
- **Face Value:** ₹5
- **F&O Eligible:** Yes
- **Website:** biocon.com

## About

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

## Latest Price

- **Price:** ₹390.65
- **Change:** -1 (-0.26%)
- **Open:** ₹391.55
- **Day High:** ₹396.85
- **Day Low:** ₹384.65
- **Previous Close:** ₹391.65
- **Volume:** 3665623
- **As Of:** 2026-09-11T10:24:07+00:00

## Key Fundamentals

Observed at 2026-09-11T04:52:52.834101Z.

- **Market Cap:** ₹62453.58 Cr
- **Classification:** Midcap
- **P/E (reported):** 152.3
- **P/E (TTM):** 116.26
- **EPS (TTM):** ₹3.36
- **EPS (reported):** ₹13
- **Book Value:** ₹211.51
- **Price to Book:** 1.84
- **Dividend Yield:** 0.13%
- **ROE:** 1.01%
- **ROCE:** 2.9%
- **Debt to Equity:** 0.45
- **Revenue (yearly):** ₹17269.5 Cr
- **Net Income:** ₹368.8 Cr
- **EBITDA:** ₹3797.8 Cr
- **52-Week High:** ₹447.15
- **52-Week Low:** ₹337.05
- **RSI (14):** 32.52

## Tapetide Score

- **Score:** 31 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Falling
- **Percentile:** 2.7 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 19.51 | 9% |
| growth | 23.73 | 9% |
| momentum | 18.27 | 12% |
| ownership | 31.98 | 24% |
| quality | 38.32 | 22% |
| valuation | 36.27 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.
- Company has a low return on equity of 3.49% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 10.9% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -16.0%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -50.9% | -32.5% | 69.47% |
| ebitda margin growth | -12.09% | -17.21% | -17.52% | -15.42% |
| net income growth | -31.12% | -74.2% | -15% | -12% |
| revenue growth | -4.2% | 4.85% | 15% | 19% |
| roce | -28.85% | -53.67% | -52.77% | 4.93% |
| roe | -31.12% | -80.43% | 3.77% | -87.61% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 3462 | 3954 | 3917 | 3433 | 3590 | 3821 | 4417 | 3942 | 4296 | 4173 | 4517 | 4336 |
| Expenses | 2745 | 3051 | 3004 | 2812 | 2905 | 3070 | 3339 | 3176 | 3460 | 3340 | 3496 | 3489 |
| Operating Profit | 717 | 903 | 913 | 620 | 685 | 752 | 1078 | 766 | 835 | 834 | 1020 | 847 |
| OPM % | 21 | 23 | 23 | 18 | 19 | 20 | 24 | 19 | 19 | 20 | 23 | 20 |
| Other Income | 134 | 587 | 40 | 1166 | 58 | 53 | 57 | 62 | 81 | -176 | -28 | 41 |
| Interest | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 | 210 | 232 | 213 |
| Depreciation | 389 | 414 | 407 | 405 | 420 | 425 | 436 | 455 | 473 | 515 | 513 | 547 |
| Profit before tax | 214 | 808 | 319 | 1146 | 98 | 156 | 487 | 97 | 171 | -68 | 248 | 128 |
| Tax % | 19 | 7 | 30 | 25 | 72 | 48 | 6 | 8 | 22 | -24 | 20 | -7 |
| Net Profit | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 | -52 | 199 | 137 |
| EPS in Rs | 1.05 | 5.5 | 1.13 | 5.49 | -0.13 | 0.21 | 2.87 | 0.23 | 0.63 | 1.08 | 0.78 | 0.87 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 4123 | 5514 | 6300 | 7143 | 8184 | 11174 | 14756 | 15262 | 16927 | 17321 |
| Expenses | 3294 | 4121 | 4696 | 5562 | 6391 | 8762 | 11540 | 12008 | 13456 | 13785 |
| Operating Profit | 829 | 1394 | 1604 | 1581 | 1793 | 2412 | 3216 | 3254 | 3471 | 3536 |
| OPM % | 20 | 25 | 25 | 22 | 22 | 22 | 22 | 21 | 21 | 20 |
| Other Income | 228 | 340 | 199 | 260 | 72 | 18 | 853 | 1217 | -76 | -82 |
| Interest | 62 | 71 | 65 | 58 | 68 | 419 | 974 | 897 | 990 | 927 |
| Depreciation | 385 | 448 | 552 | 715 | 814 | 1113 | 1569 | 1687 | 1957 | 2049 |
| Profit before tax | 610 | 1215 | 1186 | 1068 | 983 | 897 | 1525 | 1887 | 448 | 479 |
| Tax % | 26 | 17 | 27 | 21 | 22 | 28 | 15 | 24 | 18 | — |
| Net Profit | 453 | 1003 | 871 | 846 | 772 | 643 | 1298 | 1429 | 369 | 416 |
| EPS in Rs | 3.1 | 7.54 | 6.24 | 6.17 | 5.4 | 3.85 | 8.52 | 8.44 | 2.38 | 3.36 |
| Dividend Payout % | 16 | 7 | 0 | 0 | 9 | 39 | 6 | 6 | 21 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 | 810 |
| Reserves | 4738 | 4881 | 5798 | 6106 | 7027 | 7832 | 17267 | 19183 | 21044 | 33221 |
| Borrowings | 2302 | 2264 | 2422 | 2715 | 4481 | 5147 | 18019 | 16277 | 18362 | 15434 |
| Other Liabilities | 2254 | 2545 | 3672 | 4993 | 6382 | 6763 | 15856 | 19693 | 18534 | 13943 |
| Total Liabilities | 9394 | 9990 | 12192 | 14414 | 18490 | 20342 | 51742 | 55753 | 58540 | 63409 |
| Fixed Assets | 3626 | 3700 | 4471 | 5971 | 6364 | 6569 | 29468 | 30644 | 31963 | 36486 |
| CWIP | 839 | 1303 | 1899 | 2196 | 2800 | 4110 | 7317 | 7993 | 8508 | 6987 |
| Investments | 1253 | 675 | 1012 | 966 | 1952 | 1588 | 2069 | 1000 | 1127 | 1779 |
| Other Assets | 3676 | 4312 | 4811 | 5281 | 7374 | 8074 | 12888 | 16117 | 16941 | 18157 |
| Total Assets | 9394 | 9990 | 12192 | 14414 | 18490 | 20342 | 51742 | 55753 | 58540 | 63409 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 640 | 662 | 1155 | 1283 | 1160 | 1177 | 1852 | 2954 | 4061 | 1994 |
| Cash from Investing Activity | -510 | -684 | -703 | -1505 | -3651 | -1662 | -14260 | -1002 | -203 | -1883 |
| Cash from Financing Activity | -178 | -240 | -242 | 388 | 2564 | 242 | 13049 | -2333 | -1854 | -924 |
| Net Cash Flow | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 | 2004 | -812 |
| Free Cash Flow | 32 | -251 | -337 | -546 | -577 | -746 | 129 | 1046 | 1718 | 82 |
| CFO/OP | 86 | 104 | 104 | 101 | 86 | 80 | 86 | 101 | 139 | 64 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 83 | 94 | 86 | 71 | 77 | 92 | 117 | 154 | 131 | 129 |
| Inventory Days | 160 | 161 | 199 | 263 | 304 | 309 | 423 | 368 | 346 | 390 |
| Days Payable | 187 | 224 | 231 | 243 | 246 | 216 | 383 | 467 | 460 | 434 |
| Cash Conversion Cycle | 57 | 31 | 53 | 91 | 134 | 184 | 157 | 55 | 18 | 85 |
| Working Capital Days | 24 | 6 | -2 | -31 | 8 | 71 | 3 | -68 | -63 | -17 |
| ROCE % | 12 | 8 | 13 | 13 | 10 | 9 | 6 | 6 | 6 | 4 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 54.45% | 54.45% | 54.45% | 44.91% | 44.68% |
| FIIs | 7.96% | 6.55% | 5.63% | 5.9% | 5.93% | 5.66% | 5.66% | 6.04% | 6.61% | 7.39% | 7.52% | 8.14% |
| DIIs | 14.08% | 14.51% | 13.68% | 14.3% | 14.44% | 15.37% | 15.72% | 22.82% | 22.1% | 21.71% | 24.07% | 23.38% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 13.61% | 14.47% | 15.53% | 14.63% | 14.57% | 14.07% | 13.63% | 12.58% | 12.71% | 12.38% | 10.01% | 10.26% |
| Others | 3.7% | 3.83% | 4.52% | 4.53% | 4.42% | 4.27% | 4.34% | 4.1% | 4.12% | 4.06% | 13.49% | 13.54% |
| No. of Shareholders | 415046 | 434339 | 470261 | 443513 | 439503 | 427705 | 424297 | 430217 | 413191 | 394279 | 386593 | 392509 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 3 / 4 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 397.45 | Sell |
| EMA (10) | 397.51 | Sell |
| SMA (20) | 405.92 | Sell |
| EMA (20) | 404.31 | Sell |
| SMA (50) | 418.35 | Sell |
| EMA (50) | 411.7 | Sell |
| SMA (100) | 412.47 | Sell |
| EMA (100) | 408.61 | Sell |
| SMA (200) | 395.7 | Sell |
| EMA (200) | 397.09 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 31.87 | Neutral |
| MACD (12,26,9) | -8.02 | Sell |
| Stochastic (14,3,3) | 15.05 | Buy |
| ADX (14) | 16.78 | Neutral |
| Williams %R (14) | -83.76 | Buy |
| ATR (14) | 8.92 | Neutral |
| ROC (12) | -6.43 | Sell |
| Stoch RSI (14) | 9.99 | Buy |
| UO (7,14,28) | 34.61 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 7 | 43.75% |
| Hold | 3 | 18.75% |
| Sell | 6 | 37.5% |

Based on 16 analyst ratings, observed at 2026-09-11T04:52:52.885072+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Communication Regarding Remittance Of Final Dividend For The FY 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=00964635-ca0b-4612-84a4-44fa2690c86e.pdf) |
| 2026-09-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=836b0eed-9c97-4363-95f9-21d0e9d6bd4d.pdf) |
| 2026-09-08 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=26aea004-257c-4a71-980b-b9892e372008.pdf) |
| 2026-08-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9c57fef6-4235-4063-b33a-a4479d5cd35b.pdf) |
| 2026-08-28 | [Communication Regarding Remittance Of Final Dividend For The FY 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=870bf080-ecb5-491e-a5d7-d963533959a2.pdf) |
| 2026-08-26 | [Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=B282515F_9212_4278_A84F_870110833B39_145127.pdf) |
| 2026-08-25 | [Company Statement](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dae93049-d1c1-491f-addf-24722e9c8b7b.pdf) |
| 2026-08-18 | [Company Statement](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66657020-ac6e-459e-8527-d692d969edcf.pdf) |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3b7487c-0a30-4bc8-a08a-eee529c650e9.pdf) |
| 2026-08-08 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fea4fde3-ed0e-4cfa-9923-9e07fe80597e.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=22f6a57c-f160-4859-9738-7a2c5e85d707.pdf) |
| 2026-05-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6697876b-b9de-4a2f-aad9-1b7918f96bad.pdf) |
| 2026-02-17 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=405a8c62-a9a3-4d2d-877d-e7d9beb38799.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1a0caa23-9d2d-44a3-a304-f7d0c7d81aa3.pdf) |
| 2026-05-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=19b6dcc7-0a98-42db-9cec-765a1054ac34.pdf) |
| 2026-02-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2c50b86-6cd0-4707-98eb-202a7ea72e16.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=efa611b7-1ebd-4f22-ad38-405b2a9a10f4.pdf) |
| 2025-08-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=15c7c3c0-2053-4747-8e2d-1c15adba4a81.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6895e1e1-212a-457e-bc40-d3758dcf17bb.pdf) |
| 2026-06-01 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=13cb4b2b-18c3-4c8c-bd02-2f41dbd6eb34.pdf) |
| 2026-05-08 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cd77dab-72a2-4ccd-b4c1-ebcc8bb63d60.pdf) |
| 2026-02-25 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3ee51ce5-7b92-4aea-82de-9ccc0e3d0818.pdf) |
| 2026-02-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=da900c6c-2204-4fe1-9b32-e56558e00b7f.pdf) |
| 2025-12-09 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2ff782cb-ade9-4f58-910a-f6fcdc89cc55.pdf) |
| 2025-12-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2c6f003d-2a2f-4c28-89fa-fe83b1e31f46.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a2a272c9-3495-4e33-81c5-a3d9ec77cfc2.pdf) |
| 2025-08-08 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d463313-de41-416f-8dc6-428934f9a499.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-05 | [Outcome Of Board Meeting-Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=48f1f755-3624-416a-a97b-73ab08c8321d.pdf) |
| 2026-05-07 | [Outcome Of Board Meeting-Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31ac1d69-2af2-4410-b744-07703d830770.pdf) |
| 2026-02-12 | [Outcome Of Board Meeting-Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=915aa19c-1c8c-47f8-8297-e7b7b8c8984f.pdf) |
| 2025-11-11 | [Financial Results For Quarter And Half Year Ended 30 September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec5d9533-ca7c-4d8b-ba32-3c7c3d36a849.pdf) |
| 2025-08-07 | [Financial Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7be3f098-c01e-461e-af89-23b9691f2341.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a2a272c9-3495-4e33-81c5-a3d9ec77cfc2.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a4b4bb9f-bbd1-4594-855d-bda8bbe3984b.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/6697876b-b9de-4a2f-aad9-1b7918f96bad.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3cd77dab-72a2-4ccd-b4c1-ebcc8bb63d60.pdf) |
| Jun 2026 | [Concall - Jun 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6697876b-b9de-4a2f-aad9-1b7918f96bad.pdf) |
| Jan 2026 | [Concall - Jan 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/303452a6-6035-4dc6-9e0f-5c9b5a0c31ad.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/da900c6c-2204-4fe1-9b32-e56558e00b7f.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/405a8c62-a9a3-4d2d-877d-e7d9beb38799.pdf) |
| Dec 2025 | [Concall - Dec 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7bec0c0b-8e39-4087-b794-710c26772ed1.pdf) |
| Dec 2025 | [Concall - Dec 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d83ed212-a423-478e-baca-d9c9f220ebff.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 May - Biocon seeks shareholder approval for CEO appointment, board changes, and issue 87,92,317 shares for BBL swap. | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 9 May - Biocon seeks shareholder approval for CEO appointment, board changes, and issue 87,92,317 shares for BBL swap.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/c44009c9-095a-4a5c-bc0d-b6fce2f1a986.pdf) |
| 8 May - Biocon shared audio and video recordings of its Q4 FY26 earnings call held on May 08, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 8 May - Biocon shared audio and video recordings of its Q4 FY26 earnings call held on May 08, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/19b6dcc7-0a98-42db-9cec-765a1054ac34.pdf) |
| 8 Apr - Biocon Pharma получила U.S. FDA approval for Dapagliflozin tablets 5 mg and 10 mg on April 8, 2026. | [Company Statement 8 Apr - Biocon Pharma получила U.S. FDA approval for Dapagliflozin tablets 5 mg and 10 mg on April 8, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/76e3590a-00b0-4ff6-83bf-0de5d6a940b9.pdf) |
| 7h - Board to approve Q4 FY26 results on May 7; earnings call on May 8. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 7h - Board to approve Q4 FY26 results on May 7; earnings call on May 8.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/c2687b66-a09b-4327-9787-8cec47c9c1f1.pdf) |
| 7h - Board meets May 7, 2026 for audited FY26 results, possible dividend; earnings call May 8. | [Board Meeting Intimation for Intimation Of The Board Meeting And Earnings Conference Call For Analysts And Investors 7h - Board meets May 7, 2026 for audited FY26 results, possible dividend; earnings call May 8.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/b313eb72-2a2b-4f93-b747-99778972e4af.pdf) |
| 7 Apr - Biocon schedules investor meetings in Hong Kong and Singapore on 14-17 Apr 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 7 Apr - Biocon schedules investor meetings in Hong Kong and Singapore on 14-17 Apr 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b1e02ff5-d1bf-4b24-8c6f-33f70fcb9352.pdf) |
| 7 Apr - Biocon launches Bosaya and Aukelso denosumab biosimilars commercially in the U.S. after September 2025 FDA approval. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 7 Apr - Biocon launches Bosaya and Aukelso denosumab biosimilars commercially in the U.S. after September 2025 FDA approval.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4d988452-9da4-48cd-89bc-f2fa0f5fb76f.pdf) |
| 7 Apr - Biocon filed Regulation 74(5) certificate for quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Biocon filed Regulation 74(5) certificate for quarter ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/75f024ff-dacb-49a6-81e3-1793b943e4bb.pdf) |
| 6h - Biocon reminds physical shareholders to update KYC details; dividends may be withheld if not updated. | [Reminder Letter To Shareholders Holding Shares In Physical Form For Furnishing Of KYC Details 6h - Biocon reminds physical shareholders to update KYC details; dividends may be withheld if not updated.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/1f298131-96d7-4f4a-952c-4b48bb63f2ff.pdf) |
| 6 Feb - Schedule of Analysts / Investor Meetings to be held on February 11, 2026 and February 13, 2026 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 6 Feb - Schedule of Analysts / Investor Meetings to be held on February 11, 2026 and February 13, 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/63b59aa8-b0b2-49eb-b872-3b3133c24380.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9aba3fcb-dde3-468b-bf62-f3f17a0434e0.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T20:15:41.444Z.